Cavion Announces First Patient Enrolled In Its Multi-Center Phase II Clinical Trial In Essential Tremor

Published: Sep 20, 2017

Introducing a new therapeutic approach for patients with movement disorders

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Cavion, Inc. announced today that the first patient has been enrolled in its new T-CALM Study (Tremor Cav3 Modulation Study), a Phase 2 clinical trial using the company’s T-type calcium channel modulator CX-8998 for patients with Essential Tremor (ET).

Movement disorders like Essential Tremor are associated with abnormal activity of the brain’s neural networks. T-type calcium channels, called Cav3, control the firing and signaling between neurons. CX-8998 is an oral drug that was designed to selectively modulate these calcium channels, restoring the brain’s natural rhythms. Data from preclinical models suggest that CX-8998 reduces tremor by regulating abnormal neural activity in relevant brain regions.

“We are excited to enroll the first patient with Cavion’s first-in-class agent for movement disorders,” said Cavion CEO and President Andrew Krouse. “We believe that Cavion’s new therapy may significantly improve the quality of life of people with Essential Tremor, offering hope to them and their families,” added Spyros Papapetropoulos, Cavion's Executive Vice President of Research & Development and Chief Medical Officer.

“There is a tremendous need for new, safe, and effective treatments for essential tremor. The International Essential Tremor Foundation (IETF) is pleased to see a promising new approach studied in such a robust clinical trial for people with essential tremor,” said Foundation Executive Director Patrick McCartney.

About the T-CALM Study

T-CALM is a multi-center randomized, double-blind, placebo-controlled study designed to assess the efficacy of CX-8998 in reducing tremors and improving quality of life. The study will enroll up to 92 patients at 18 medical research centers across the United States. The study will utilize a combination of standard clinical trial scales and state-of-the-art digital biomarkers to objectively quantify tremor. The effect of CX-8998 on neuronal networks will be further explored in a planned sub-study using electrophysiological measures.

About Essential Tremor

Essential Tremor is the most common movement disorder and causes progressively disabling rhythmic trembling of the hands, head, voice, legs or trunk. ET affects an estimated 10 million Americans of all ages and millions more worldwide. Tremor usually interferes with typical activities of daily living such as feeding, drinking, grooming and writing. ET represents a major source of disability and social isolation. There is low public awareness of the disease and high unmet need in ET. It is estimated that up to 50% of people with ET report lack of efficacy from oral prescription medication and up to one-third who respond discontinue therapy due to side-effects.

About Cavion, Inc.

Cavion, Inc. is a privately held clinical stage biotechnology company creating therapies modulating the T-type calcium channel (Cav3) for the treatment of neurological diseases. Cavion’s platform of Cav3 modulators restore the brain’s natural rhythms in a variety of chronic neurological diseases such as essential tremor, Parkinson’s disease, neuropathic pain, and epilepsy as well as orphan and rare neuro-developmental and genetic disorders.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Cavion, Inc. disclaims any intent or obligation to update forward-looking statements, except as required by law.

Cavion, Inc.
Andrew Krouse, 434-974-6969
krouse@cavionpharma.com
www.cavionpharma.com

Back to news